These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

276 related items for PubMed ID: 31092443

  • 1. An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
    Kaira K, Imai H, Souma R, Sakurai R, Miura Y, Sunaga N, Kasahara N, Tsukagoshi Y, Koga Y, Kitahara S, Kotake M, Minato K, Naruse I, Fukushima Y, Hisada T, Ishizuka T.
    Anticancer Res; 2019 May; 39(5):2483-2491. PubMed ID: 31092443
    [Abstract] [Full Text] [Related]

  • 2. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
    Miyanaga A, Kubota K, Hosomi Y, Okuma Y, Minato K, Fujimoto S, Okamoto H, Satouchi M, Isobe H, Aono H, Takiguchi Y, Gemma A, Tokyo Cooperative Oncology Group.
    Jpn J Clin Oncol; 2019 Aug 01; 49(8):749-754. PubMed ID: 31070750
    [Abstract] [Full Text] [Related]

  • 3. Pemetrexed/Carboplatin/Bevacizumab followed by Maintenance Pemetrexed/Bevacizumab in Hispanic Patients with Non-Squamous Non-Small Cell Lung Cancer: Outcomes according to Thymidylate Synthase Expression.
    Cardona AF, Rojas L, Wills B, Arrieta O, Carranza H, Vargas C, Otero J, Cuello M, Corrales L, Martín C, Ortiz C, Franco S, Rosell R, CLICaP.
    PLoS One; 2016 Aug 01; 11(5):e0154293. PubMed ID: 27191954
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer.
    Fukushima T, Wakatsuki Y, Kobayashi T, Sonehara K, Tateishi K, Yamamoto M, Masubuchi T, Yoshiike F, Hirai K, Hachiya T, Koizumi T.
    Cancer Chemother Pharmacol; 2018 Jun 01; 81(6):1043-1050. PubMed ID: 29644460
    [Abstract] [Full Text] [Related]

  • 5. Phase II trial of induction chemotherapy of pemetrexed plus split-dose cisplatin followed by pemetrexed maintenance for untreated non-squamous non-small-cell lung cancer.
    Koba T, Minami S, Nishijima-Futami Y, Masuhiro K, Kimura H, Futami S, Yaga M, Mori M, Kagawa H, Uenami T, Kohmo S, Otsuka T, Yamamoto S, Komuta K, Kijima T.
    Cancer Chemother Pharmacol; 2018 Jul 01; 82(1):111-117. PubMed ID: 29728800
    [Abstract] [Full Text] [Related]

  • 6. Switch maintenance therapy with docetaxel and bevacizumab after induction therapy with cisplatin, pemetrexed, and bevacizumab in advanced non-squamous non-small cell lung cancer: a phase II study.
    Nishimoto K, Karayama M, Inui N, Yasui H, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inami N, Matsuura S, Kaida Y, Matsui T, Asada K, Matsuda H, Fujii M, Toyoshima M, Imokawa S, Suda T.
    Med Oncol; 2018 Jun 16; 35(7):108. PubMed ID: 29909581
    [Abstract] [Full Text] [Related]

  • 7. Randomized phase II study of chemoradiotherapy with cisplatin + S-1 versus cisplatin + pemetrexed for locally advanced non-squamous non-small cell lung cancer: SPECTRA study.
    Niho S, Yoshida T, Akimoto T, Sakamaki K, Ono A, Seto T, Nishio M, Yamamoto N, Hida T, Okamoto H, Kurata T, Satouchi M, Goto K, Yamanaka T, Ohe Y.
    Lung Cancer; 2020 Mar 16; 141():64-71. PubMed ID: 31955002
    [Abstract] [Full Text] [Related]

  • 8. Maintenance therapy with pemetrexed and bevacizumab versus pemetrexed monotherapy after induction therapy with carboplatin, pemetrexed, and bevacizumab in patients with advanced non-squamous non small cell lung cancer.
    Karayama M, Inui N, Fujisawa T, Enomoto N, Nakamura Y, Kuroishi S, Yokomura K, Koshimizu N, Sato M, Toyoshima M, Shirai T, Masuda M, Yamada T, Imokawa S, Suda T.
    Eur J Cancer; 2016 May 16; 58():30-7. PubMed ID: 26922170
    [Abstract] [Full Text] [Related]

  • 9. Phase II Trial of Carboplatin and Pemetrexed Plus Bevacizumab with Maintenance Bevacizumab as a First-line Treatment for Advanced Non-squamous Non-small Cell Lung Cancer in Elderly Patients.
    Takeoka H, Yamada K, Naito Y, Matsuo N, Ishii H, Tokito T, Azuma K, Ichiki M, Hoshino T.
    Anticancer Res; 2018 Jun 16; 38(6):3779-3784. PubMed ID: 29848743
    [Abstract] [Full Text] [Related]

  • 10. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial.
    Paz-Ares L, de Marinis F, Dediu M, Thomas M, Pujol JL, Bidoli P, Molinier O, Sahoo TP, Laack E, Reck M, Corral J, Melemed S, John W, Chouaki N, Zimmermann AH, Visseren-Grul C, Gridelli C.
    Lancet Oncol; 2012 Mar 16; 13(3):247-55. PubMed ID: 22341744
    [Abstract] [Full Text] [Related]

  • 11. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
    Nishino K, Imamura F, Kumagai T, Katakami N, Hata A, Okuda C, Urata Y, Hattori Y, Tachihara M, Yokota S, Nishimura T, Kaneda T, Satouchi M, Morita S, Negoro S.
    Lung Cancer; 2015 Aug 16; 89(2):146-53. PubMed ID: 26093793
    [Abstract] [Full Text] [Related]

  • 12. Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer.
    Kaira K, Tomizawa Y, Yoshino R, Miura Y, Yoshii A, Iwasaki Y, Koga Y, Ono A, Hisada T, Minato K, Sato K, Kazama T, Ishihara S, Kohyama K, Fueki N, Saito R, Sunaga N.
    Lung Cancer; 2013 Oct 16; 82(1):103-8. PubMed ID: 23927884
    [Abstract] [Full Text] [Related]

  • 13. Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study.
    Tsutani Y, Miyata Y, Masuda T, Fujitaka K, Doi M, Awaya Y, Kuyama S, Kitaguchi S, Ueda K, Hattori N, Okada M.
    BMC Cancer; 2018 Dec 10; 18(1):1231. PubMed ID: 30526545
    [Abstract] [Full Text] [Related]

  • 14. A randomized phase 3 study of maintenance therapy with S-1 plus best supportive care versus best supportive care after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L).
    Tanaka K, Morita S, Ando M, Yokoyama T, Nakamura A, Yoshioka H, Ishiguro T, Miura S, Toyozawa R, Oguri T, Daga H, Ko R, Bessho A, Tachihara M, Iwamoto Y, Hirano K, Nakanishi Y, Nakagawa K, Yamamoto N, Okamoto I.
    Cancer; 2020 Aug 15; 126(16):3648-3656. PubMed ID: 32484914
    [Abstract] [Full Text] [Related]

  • 15. A phase IB dose-escalation study of the safety and pharmacokinetics of pictilisib in combination with either paclitaxel and carboplatin (with or without bevacizumab) or pemetrexed and cisplatin (with or without bevacizumab) in patients with advanced non-small cell lung cancer.
    Soria JC, Adjei AA, Bahleda R, Besse B, Ferte C, Planchard D, Zhou J, Ware J, Morrissey K, Shankar G, Lin W, Schutzman JL, Dy GK, Groen HJM.
    Eur J Cancer; 2017 Nov 15; 86():186-196. PubMed ID: 28992562
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase III trial of maintenance bevacizumab with or without pemetrexed after first-line induction with bevacizumab, cisplatin, and pemetrexed in advanced nonsquamous non-small-cell lung cancer: AVAPERL (MO22089).
    Barlesi F, Scherpereel A, Rittmeyer A, Pazzola A, Ferrer Tur N, Kim JH, Ahn MJ, Aerts JG, Gorbunova V, Vikström A, Wong EK, Perez-Moreno P, Mitchell L, Groen HJ.
    J Clin Oncol; 2013 Aug 20; 31(24):3004-11. PubMed ID: 23835708
    [Abstract] [Full Text] [Related]

  • 17. Phase1 study of cisplatin plus pemetrexed with erlotinib and bevacizumab for chemotherapy-naïve advanced non-squamous non-small cell lung cancer with EGFR mutations.
    Tamiya M, Tamiya A, Shiroyama T, Takeoka S, Naito Y, Omachi N, Kimura Y, Morishita N, Suzuki H, Okamoto N, Okishio K, Kawaguchi T, Atagi S, Hirashima T.
    Invest New Drugs; 2018 Aug 20; 36(4):608-614. PubMed ID: 29101518
    [Abstract] [Full Text] [Related]

  • 18. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09.
    Gautschi O, Mach N, Rothschild SI, Li Q, Stahel RA, Zippelius A, Cathomas R, Früh M, Betticher DC, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut EO, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein AF, Swiss Group for Clinical Cancer Research.
    Clin Lung Cancer; 2015 Sep 20; 16(5):358-65. PubMed ID: 25843489
    [Abstract] [Full Text] [Related]

  • 19. Efficacy and Safety of Onartuzumab in Combination With First-Line Bevacizumab- or Pemetrexed-Based Chemotherapy Regimens in Advanced Non-Squamous Non-Small-Cell Lung Cancer.
    Wakelee H, Zvirbule Z, De Braud F, Kingsley CD, Mekhail T, Lowe T, Schütte W, Lena H, Lawler W, Braiteh F, Cosgriff T, Kaen D, Boyer M, Hsu J, Phan S, Novello S.
    Clin Lung Cancer; 2017 Jan 20; 18(1):50-59. PubMed ID: 27856142
    [Abstract] [Full Text] [Related]

  • 20. A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101).
    Takashina T, Asahina H, Oizumi S, Yamada N, Harada M, Takamura K, Yokouchi H, Harada T, Honjo O, Ogi T, Morikawa N, Kinoshita I, Honda R, Nakano K, Kanazawa K, Amano T, Dosaka-Akita H, Isobe H, Nishimura M, Hokkaido Lung Cancer Clinical Study Group.
    Int J Clin Oncol; 2018 Dec 20; 23(6):1060-1069. PubMed ID: 30027464
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.